Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

The Evaluation of the Ameliorative Effect of Montelukast Against Arsenic Trioxide-Induced Cardiotoxicity in Rats

Ali Asghar Hemmati 1 , Samaneh Olapour 2 , * , Hossein Najafzadeh Varzi 3 , Mohammad Javad Khodayar 4 , Mahin Dianat 5 , Babak Mohammadian 6 and Hamid Yaghooti 7
Authors Information
1 Department of Pharmacology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
2 Department of Pharmacology, Health Research Institute, Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
3 Department of Pharmacology, Shahid Chamran University, Ahvaz, IR Iran
4 Department of Toxicology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
5 Physiology Research Center and Department of Physiology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
6 Department of Pathobiology, Shahid Chamram University, Ahvaz, IR Iran
7 Department of Medical Laboratory Sciences, Jundishapur University of Medical Sciences, Ahvaz, IR Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: November 2017, 12 (4); e65046
  • Published Online: December 23, 2017
  • Article Type: Research Article
  • Received: June 18, 2016
  • Revised: December 10, 2016
  • Accepted: January 9, 2017
  • DOI: 10.5812/jjnpp.65046

To Cite: Hemmati A A, Olapour S, Najafzadeh Varzi H, Khodayar M J, Dianat M, et al. The Evaluation of the Ameliorative Effect of Montelukast Against Arsenic Trioxide-Induced Cardiotoxicity in Rats, Jundishapur J Nat Pharm Prod. 2017 ; 12(4):e65046. doi: 10.5812/jjnpp.65046.

Abstract
Copyright © 2017, Jundishapur Journal of Natural Pharmaceutical Products. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
References
  • 1. Miao X, Tang Z, Wang Y, Su G, Sun W, Wei W, et al. Metallothionein prevention of arsenic trioxide-induced cardiac cell death is associated with its inhibition of mitogen-activated protein kinases activation in vitro and in vivo. Toxicol Lett. 2013;220(3):277-85. doi: 10.1016/j.toxlet.2013.04.025. [PubMed: 23664956].
  • 2. Zhang J, Wang B. Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo. Gynecol Oncol. 2006;103(1):199-206. doi: 10.1016/j.ygyno.2006.02.037. [PubMed: 16624393].
  • 3. Antman KH. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist. 2001;6 Suppl 2:1-2. doi: 10.1634/theoncologist.6-suppl_2-1. [PubMed: 11331433].
  • 4. Flora SJ. Arsenic-induced oxidative stress and its reversibility. Free Radic Biol Med. 2011;51(2):257-81. doi: 10.1016/j.freeradbiomed.2011.04.008. [PubMed: 21554949].
  • 5. Zhao X, Feng T, Chen H, Shan H, Zhang Y, Lu Y, et al. Arsenic trioxide-induced apoptosis in H9c2 cardiomyocytes: implications in cardiotoxicity. Basic Clin Pharmacol Toxicol. 2008;102(5):419-25. doi: 10.1111/j.1742-7843.2007.00150.x. [PubMed: 18346055].
  • 6. Shan H, Zhang Y, Cai B, Chen X, Fan Y, Yang L, et al. Upregulation of microRNA-1 and microRNA-133 contributes to arsenic-induced cardiac electrical remodeling. Int J Cardiol. 2013;167(6):2798-805. doi: 10.1016/j.ijcard.2012.07.009. [PubMed: 22889704].
  • 7. Kucukkurt I, Ince S, Demirel HH, Turkmen R, Akbel E, Celik Y. The Effects of Boron on Arsenic-Induced Lipid Peroxidation and Antioxidant Status in Male and Female Rats. J Biochem Mol Toxicol. 2015;29(12):564-71. doi: 10.1002/jbt.21729. [PubMed: 26184899].
  • 8. Saad SY, Alkharfy KM, Arafah MM. Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats. J Pharm Pharmacol. 2006;58(4):567-73. doi: 10.1211/jpp.58.4.0017. [PubMed: 16597375].
  • 9. Khodayar MJ, Javadipour M, Keshtzar E, Rezaei M. Role of berberine against arsenic induced oxidative damage in isolated rat liver mitochondria. J Environ Biol. 2016;37(2):285-90. [PubMed: 27097449].
  • 10. Dianat M, Amini N, Badavi M, Farbood Y. Ellagic acid improved arrhythmias induced by CaCL2 in the rat stress model. Avicenna J Phytomed. 2015;5(2):120-7. [PubMed: 25949953].
  • 11. Shafik NM, El Batsh MM. Protective Effects of Combined Selenium and Punica granatum Treatment on Some Inflammatory and Oxidative Stress Markers in Arsenic-Induced Hepatotoxicity in Rats. Biol Trace Elem Res. 2016;169(1):121-8. doi: 10.1007/s12011-015-0397-1. [PubMed: 26085057].
  • 12. De Vizcaya-Ruiz A, Barbier O, Ruiz-Ramos R, Cebrian ME. Biomarkers of oxidative stress and damage in human populations exposed to arsenic. Mutat Res. 2009;674(1-2):85-92. doi: 10.1016/j.mrgentox.2008.09.020. [PubMed: 18984063].
  • 13. Badavi M, Sadeghi N, Dianat M, Samarbafzadeh A. Effects of gallic Acid and cyclosporine a on antioxidant capacity and cardiac markers of rat isolated heart after ischemia/reperfusion. Iran Red Crescent Med J. 2014;16(6). e16424. doi: 10.5812/ircmj.16424. [PubMed: 25068044].
  • 14. Ahmed AA. Protective effect of montelukast on paraquat-induced lung toxicity in rats. Biosci Trends. 2009;3(2):63-72. [PubMed: 20103949].
  • 15. Hemmati AA, Ghorbanzadeh B, Behmanesh MA. Potentiation of indomethacin-induced anti-inflammatory response by montelukast in formalin-induced inflammation in rats. Acta Med Iran. 2013;51(10):675-80. [PubMed: 24338138].
  • 16. Cuciureanu M, Caruntu ID, Paduraru O, Stoica B, Jerca L, Crauciuc E, et al. The protective effect of montelukast sodium on carbon tetrachloride induced hepatopathy in rat. Prostaglandins Other Lipid Mediat. 2009;88(3-4):82-8. doi: 10.1016/j.prostaglandins.2008.10.004. [PubMed: 19041730].
  • 17. Kuru S, Kismet K, Barlas AM, Tuncal S, Celepli P, Surer H, et al. The Effect of Montelukast on Liver Damage in an Experimental Obstructive Jaundice Model. Viszeralmedizin. 2015;31(2):131-8. doi: 10.1159/000375434. [PubMed: 26989383].
  • 18. Al Saadi MM, Meo SA, Mustafa A, Shafi A, Tuwajri AS. Effects of Montelukast on free radical production in whole blood and isolated human polymorphonuclear neutrophils (PMNs) in asthmatic children. Saudi Pharm J. 2011;19(4):215-20. doi: 10.1016/j.jsps.2011.06.002. [PubMed: 23960762].
  • 19. Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax. 2008;63(5):453-62. doi: 10.1136/thx.2007.081596. [PubMed: 18443162].
  • 20. Shah S, Mohan M, Kasture S, Sanna C, Maxia A. Protective effect of Ephedra nebrodensis on doxorubicin-induced cardiotoxicity in rats. Iran J Pharmacol Ther. 2009;8(2):61-6.
  • 21. Robertson IM, Sun YB, Li MX, Sykes BD. A structural and functional perspective into the mechanism of Ca2+-sensitizers that target the cardiac troponin complex. J Mol Cell Cardiol. 2010;49(6):1031-41. doi: 10.1016/j.yjmcc.2010.08.019. [PubMed: 20801130].
  • 22. Takeda S, Yamashita A, Maeda K, Maeda Y. Structure of the core domain of human cardiac troponin in the Ca(2+)-saturated form. Nature. 2003;424(6944):35-41. doi: 10.1038/nature01780. [PubMed: 12840750].
  • 23. Wang CH, Chen CL, Hsiao CK, Chiang FT, Hsu LI, Chiou HY, et al. Arsenic-induced QT dispersion is associated with atherosclerotic diseases and predicts long-term cardiovascular mortality in subjects with previous exposure to arsenic: A 17-Year follow-up study. Cardiovasc Toxicol. 2010;10(1):17-26. doi: 10.1007/s12012-009-9059-x. [PubMed: 19957052].
  • 24. Drolet B, Simard C, Roden DM. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation. 2004;109(1):26-9. doi: 10.1161/01.CIR.0000109484.00668.CE. [PubMed: 14691044].
  • 25. Dengiz GO, Odabasoglu F, Halici Z, Cadirci E, Suleyman H. Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats. J Pharmacol Sci. 2007;105(1):94-102. doi: 10.1254/jphs.FP0070122. [PubMed: 17895592].
  • 26. Ersahin M, Cevik O, Akakin D, Sener A, Ozbay L, Yegen BC, et al. Montelukast inhibits caspase-3 activity and ameliorates oxidative damage in the spinal cord and urinary bladder of rats with spinal cord injury. Prostaglandins Other Lipid Mediat. 2012;99(3-4):131-9. doi: 10.1016/j.prostaglandins.2012.09.002. [PubMed: 22986158].
  • 27. Anderson R, Theron AJ, Gravett CM, Steel HC, Tintinger GR, Feldman C. Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism. Br J Pharmacol. 2009;156(1):105-15. doi: 10.1111/j.1476-5381.2008.00012.x. [PubMed: 19068077].
  • 28. Khodir AE, Ghoneim HA, Rahim MA, Suddek GM. Montelukast attenuates lipopolysaccharide-induced cardiac injury in rats. Hum Exp Toxicol. 2016;35(4):388-97. doi: 10.1177/0960327115591372. [PubMed: 26089034].
  • 29. Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med. 2004;36(10):1199-207. doi: 10.1016/j.freeradbiomed.2004.02.074. [PubMed: 15110384].
  • 30. Cooper KL, Liu KJ, Hudson LG. Enhanced ROS production and redox signaling with combined arsenite and UVA exposure: contribution of NADPH oxidase. Free Radic Biol Med. 2009;47(4):381-8. doi: 10.1016/j.freeradbiomed.2009.04.034. [PubMed: 19414066].
  • 31. Flora SJ, Mehta A, Gupta R. Prevention of arsenic-induced hepatic apoptosis by concomitant administration of garlic extracts in mice. Chem Biol Interact. 2009;177(3):227-33. doi: 10.1016/j.cbi.2008.08.017. [PubMed: 18834867].
  • 32. Manna P, Sinha M, Sil PC. Arsenic-induced oxidative myocardial injury: protective role of arjunolic acid. Arch Toxicol. 2008;82(3):137-49. doi: 10.1007/s00204-007-0272-8. [PubMed: 18197399].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments